ATC CODE
- C09CA
INDICATION AND NEMLC RECOMMENDATIONS
INDICATION AND NEMLC RECOMMENDATION 1
INDICATION
- Add on therapy in cardiac failure on patients already on standard treatment including ACE-inhibitors, ß-Blockers and spironolactone.
RECOMMENDATION
- Not Approved
REVIEW INDICATORS
- New efficacy data from large RCT indicating larger benefit of adding ARBs to standard therapy
- Decrease in price of ARBs so as to be similarly priced to ACE-inhibitors
DATE RATIFIED
- 20 September 2007
INDICATION AND NEMLC RECOMMENDATION 2
INDICATION
- As add on therapy in proteinuric nephropathies in patients already using an ACE-inhibitor.
RECOMMENDATION
- Not Approved
Insufficient evidence to support its use.
REVIEW INDICATORS
- New evidence indicating benefit in the form of a RCT of sufficient size with maximal doses of ACE-inhibitor used.
- New safety concerns.
- Decrease in price so as to be similarly priced to ACE-inhibitors.
DATE RATIFIED
- 20 September 2007